These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 34145029)

  • 1. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer.
    Lee YS; Lee WS; Kim CW; Lee SJ; Yang H; Kong SJ; Ning J; Yang KM; Kang B; Kim WR; Chon HJ; Kim C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33199510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
    Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
    Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
    [No Abstract]   [Full Text] [Related]  

  • 5. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
    Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
    Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
    Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
    Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
    Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors.
    Xian S; Chen X; Ren S; Chen X; Wang H
    Cancer Res; 2024 Sep; 84(18):3044-3057. PubMed ID: 38990727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.
    Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
    Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
    Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.
    Tseng SH; Park ST; Lam B; Tsai YC; Cheng MA; Farmer E; Xing D; Hung CF
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
    Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
    Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.